Daniel Thomas Myran

Daniel Thomas Myran

Auto-generated profile, based on publicly available information

Daniel Thomas Myran

Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Addiction
Verified
Journal Article
Closed access
PDF file
DMDaniel T. Myran
Daniel T. Myran
MPMichael Pugliese
Michael Pugliese
PTPeter Tanuseputro
Peter Tanuseputro
NCNathan Cantor
Nathan Cantor
EREmily Rhodes
Emily Rhodes
MTMonica Taljaard
Monica Taljaard

21 July 2019 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
DMDaniel T. Myran
Daniel T. Myran
AHAmy T. Hsu
Amy T. Hsu
GSGlenys Smith
Glenys Smith
PTPeter Tanuseputro
Peter Tanuseputro
Alcohol use causes a large burden on the health of Canadians, and alcohol-related harms appear to be increasing in many high-income countries. We sought to analyze changes in emergency department visits attributable to alcohol use, by sex, age and neighbourhood income over time. All individuals aged 10 to 105 years living in Ontario, Canada, between 2003 and 2016 were included in this study. The primary outcome was age-standardized rates of emergency department visits attributable to alcohol use, defined using diagnostic codes from the Canadian Institute for Health Information Health Indicator "hospitalizations entirely caused by alcohol." We compared rates of these visits using a retrospective population-level design. Among 15 121 639 individuals, there were 765 346 emergency department visits attributable to alcohol use over the study period. Between 2003 and 2016, the age-standardized rates of these visits increased more in women (86.5%) than in men (53.2%), and the increase in rates of emergency department visits attributable to alcohol use was 4.4 times greater than the increases in the rates of overall emergency department visits. Individuals aged 25-29 years experienced the largest change in the rate of emergency department visits attributable to alcohol use (175%). We found evidence of age-cohort effects, whereby the rate of emergency department visits attributable to alcohol use at age 19 years increased on average by 4.07% (95% confidence interval [CI] 3.71%-4.44%) per year for each cohort born between 1986 and 1999. Individuals in the lowest neighbourhood income quintile had 2.37 (95% CI 2.27-2.49) times the rate of emergency department visits attributable to alcohol use than those in the highest income quintile. This disparity increased slightly over the study period. Although men and lower-income individuals have the highest burden of emergency department visits attributable to alcohol use, the largest increases in visits have been in women and younger adults. Further research should focus on potential causes of these trends to provide guidance on how to reduce alcohol-related harms.

12 July 2021 in Drug and Alcohol Review
Verified
Journal Article
Closed access
PDF file
DMDaniel T. Myran
Daniel T. Myran
ESEmiliyan Staykov
Emiliyan Staykov
NCNathan Cantor
Nathan Cantor
MTMonica Taljaard
Monica Taljaard
BQBradley I. Quach
Bradley I. Quach
PTPeter Tanuseputro
Peter Tanuseputro

EAEric Agbata
Eric Agbata
RMRachael L. Morton
Rachael L. Morton
ZBZeno Bisoffi
Zeno Bisoffi
EBEmmanuel Bottieau
Emmanuel Bottieau
CGChris Greenaway
Chris Greenaway
ARAna Requena-Méndez
Ana Requena-Méndez
We aimed to evaluate the evidence on screening and treatment for two parasitic infections—schistosomiasis and strongyloidiasis—among migrants from endemic countries arriving in the European Union and European Economic Area (EU/EEA). We conducted a systematic search of multiple databases to identify systematic reviews and meta-analyses published between 1 January 1993 and 30 May 2016 presenting evidence on diagnostic and treatment efficacy and cost-effectiveness. We conducted additional systematic search for individual studies published between 2010 and 2017. We assessed the methodological quality of reviews and studies using the AMSTAR, Newcastle–Ottawa Scale and QUADAS-II tools. Study synthesis and assessment of the certainty of the evidence was performed using GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. We included 28 systematic reviews and individual studies in this review. The GRADE certainty of evidence was low for the effectiveness of screening techniques and moderate to high for treatment efficacy. Antibody-detecting serological tests are the most effective screening tests for detection of both schistosomiasis and strongyloidiasis in low-endemicity settings, because they have higher sensitivity than conventional parasitological methods. Short courses of praziquantel and ivermectin were safe and highly effective and cost-effective in treating schistosomiasis and strongyloidiasis, respectively. Economic modelling suggests presumptive single-dose treatment of strongyloidiasis with ivermectin for all migrants is likely cost-effective, but feasibility of this strategy has yet to be demonstrated in clinical studies. The evidence supports screening and treatment for schistosomiasis and strongyloidiasis in migrants from endemic countries, to reduce morbidity and mortality.

16 September 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
DMDaniel Thomas Myran
Daniel Thomas Myran
RRRhiannon Roberts
Rhiannon Roberts
MPMichael Pugliese
Michael Pugliese
MTMonica Taljaard
Monica Taljaard
PTPeter Tanuseputro
Peter Tanuseputro
RPRosalie Liccardo Pacula
Rosalie Liccardo Pacula
Cannabis is one of the most commonly used substances in Canada and the United States: in 2019, 17.5% of individuals in the US and 21.0% of individuals in Canada reported using cannabis in the past year.1,2 There is increasing recognition that regular cannabis use is associated with various health concerns, including psychosis, anxiety, depression, altered brain functioning, and dependence.3-6 Cannabis hyperemesis syndrome (CHS) is a lesser-known complication associated with persistent use of high potency cannabis, involving repeated episodes of nausea, vomiting, and abdominal pain.7,8 To date, several studies have found increases in emergency department (ED) visits owing to vomiting or CHS after the legalization of medical or recreational cannabis.9-12 However, the characteristics of individuals with CHS have only previously been described in small studies or case series, limiting our understanding of who is at risk of this condition. In addition, there is limited information on how recreational cannabis legalization and different regulatory policies (eg, access to retail stores and product types) are associated with the frequency and severity of CHS or the clinical characteristics of individuals with CHS.

7 January 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
DMDaniel T. Myran
Daniel T. Myran
NCNathan Cantor
Nathan Cantor
YFYaron Finkelstein
Yaron Finkelstein
MPMichael Pugliese
Michael Pugliese
AGAstrid Guttmann
Astrid Guttmann
PTPeter Tanuseputro
Peter Tanuseputro
Previous studies have documented increases in cannabis exposures among young children after legalization of recreational cannabis.1-3 Increasing evidence has implicated commercially produced edible cannabis products as a key factor associated with these increases.3 Canada took a 2-phased approach to legalizing recreational cannabis. Initially, the sale of cannabis flower, seeds, and oils was permitted, and after 1 year, this expanded to a wider variety of products, including cannabis edibles.4 We evaluated changes in pediatric emergency department (ED) visits and hospitalizations due to cannabis exposures associated with these changes.